319 related articles for article (PubMed ID: 31616044)
1. Pharmacogenomics, biomarker network, and allele frequencies in colorectal cancer.
López-Cortés A; Paz-Y-Miño C; Guerrero S; Jaramillo-Koupermann G; León Cáceres Á; Intriago-Baldeón DP; García-Cárdenas JM; Guevara-Ramírez P; Armendáriz-Castillo I; Leone PE; Quiñones LA; Cayún JP; Soria NW
Pharmacogenomics J; 2020 Feb; 20(1):136-158. PubMed ID: 31616044
[TBL] [Abstract][Full Text] [Related]
2. Pharmacogenetics and pharmacogenomics as tools in cancer therapy.
Rodríguez-Vicente AE; Lumbreras E; Hernández JM; Martín M; Calles A; Otín CL; Algarra SM; Páez D; Taron M
Drug Metab Pers Ther; 2016 Mar; 31(1):25-34. PubMed ID: 26863347
[TBL] [Abstract][Full Text] [Related]
3. Pharmacogenomics of intrinsic and acquired pharmacoresistance in colorectal cancer: Toward targeted personalized therapy.
De Mattia E; Cecchin E; Toffoli G
Drug Resist Updat; 2015 May; 20():39-70. PubMed ID: 26027741
[TBL] [Abstract][Full Text] [Related]
4. Role of pharmacogenetics as predictive biomarkers of response and/or toxicity in the treatment of colorectal cancer.
Bhushan S; McLeod H; Walko CM
Clin Colorectal Cancer; 2009 Jan; 8(1):15-21. PubMed ID: 19203892
[TBL] [Abstract][Full Text] [Related]
5. Pharmacogenomics in colorectal cancer: the first step for individualized-therapy.
Bandrés E; Zárate R; Ramirez N; Abajo A; Bitarte N; Garíia-Foncillas J
World J Gastroenterol; 2007 Nov; 13(44):5888-901. PubMed ID: 17990354
[TBL] [Abstract][Full Text] [Related]
6. Host genetic profiling to increase drug safety in colorectal cancer from discovery to implementation.
Cecchin E; De Mattia E; Ecca F; Toffoli G
Drug Resist Updat; 2018 Jul; 39():18-40. PubMed ID: 30075835
[TBL] [Abstract][Full Text] [Related]
7. The role of pharmacogenetics in the new ESMO colorectal cancer guidelines.
Schirripa M; Procaccio L; Lonardi S; Loupakis F
Pharmacogenomics; 2017 Feb; 18(3):197-200. PubMed ID: 28112993
[No Abstract] [Full Text] [Related]
8. Pharmacoproteomic characterisation of human colon and rectal cancer.
Frejno M; Zenezini Chiozzi R; Wilhelm M; Koch H; Zheng R; Klaeger S; Ruprecht B; Meng C; Kramer K; Jarzab A; Heinzlmeir S; Johnstone E; Domingo E; Kerr D; Jesinghaus M; Slotta-Huspenina J; Weichert W; Knapp S; Feller SM; Kuster B
Mol Syst Biol; 2017 Nov; 13(11):951. PubMed ID: 29101300
[TBL] [Abstract][Full Text] [Related]
9. Drug resistance, predictive markers and pharmacogenomics in colorectal cancer.
Longley DB; Allen WL; Johnston PG
Biochim Biophys Acta; 2006 Dec; 1766(2):184-96. PubMed ID: 16973289
[TBL] [Abstract][Full Text] [Related]
10. Pharmacogenomic-Guided Therapy in Colorectal Cancer.
Diasio RB; Innocenti F; Offer SM
Clin Pharmacol Ther; 2021 Sep; 110(3):616-625. PubMed ID: 34114648
[TBL] [Abstract][Full Text] [Related]
11. A network-based predictive gene expression signature for recurrence risks in stage II colorectal cancer.
Yang WJ; Wang HB; Wang WD; Bai PY; Lu HX; Sun CH; Liu ZS; Guan DK; Yang GW; Zhang GL
Cancer Med; 2020 Jan; 9(1):179-193. PubMed ID: 31724326
[TBL] [Abstract][Full Text] [Related]
12. Pharmacogenetics of Anticancer Drug Sensitivity and Toxicity in Colorectal Cancer.
Moradi-Marjaneh R; Khazaei M; Seifi S; Hassanian SM; Ferns GA; Avan A
Curr Pharm Des; 2018; 24(23):2710-2718. PubMed ID: 30051785
[TBL] [Abstract][Full Text] [Related]
13. Weighted gene coexpression analysis indicates that PLAGL2 and POFUT1 are related to the differential features of proximal and distal colorectal cancer.
Lv Y; Xie B; Bai B; Shan L; Zheng W; Huang X; Zhu H
Oncol Rep; 2019 Dec; 42(6):2473-2485. PubMed ID: 31638246
[TBL] [Abstract][Full Text] [Related]
14. Pharmacogenetics research on chemotherapy resistance in colorectal cancer over the last 20 years.
Panczyk M
World J Gastroenterol; 2014 Aug; 20(29):9775-827. PubMed ID: 25110414
[TBL] [Abstract][Full Text] [Related]
15. State of Art of Cancer Pharmacogenomics in Latin American Populations.
López-Cortés A; Guerrero S; Redal MA; Alvarado AT; Quiñones LA
Int J Mol Sci; 2017 May; 18(6):. PubMed ID: 28545225
[TBL] [Abstract][Full Text] [Related]
16. MicroRNAs as novel predictive biomarkers and therapeutic targets in colorectal cancer.
Stiegelbauer V; Perakis S; Deutsch A; Ling H; Gerger A; Pichler M
World J Gastroenterol; 2014 Sep; 20(33):11727-35. PubMed ID: 25206276
[TBL] [Abstract][Full Text] [Related]
17. Colorectal cancer tumour markers and biomarkers: Recent therapeutic advances.
Lech G; Słotwiński R; Słodkowski M; Krasnodębski IW
World J Gastroenterol; 2016 Feb; 22(5):1745-55. PubMed ID: 26855534
[TBL] [Abstract][Full Text] [Related]
18. Role of miRNA gene variants in the susceptibility and pharmacogenetics of colorectal cancer.
Aghabozorgi AS; Sharif S; Jafarzadeh-Esfehani R; Vakili S; Abbaszadegan MR
Pharmacogenomics; 2021 Apr; 22(5):303-318. PubMed ID: 33733820
[TBL] [Abstract][Full Text] [Related]
19. Personalized treatment for patients with colorectal cancer: role of biomarkers.
Duffy MJ
Biomark Med; 2015; 9(4):337-47. PubMed ID: 25808438
[TBL] [Abstract][Full Text] [Related]
20. Tumour immune microenvironment biomarkers predicting cytotoxic chemotherapy efficacy in colorectal cancer.
Wilkinson K; Ng W; Roberts TL; Becker TM; Lim SH; Chua W; Lee CS
J Clin Pathol; 2021 Oct; 74(10):625-634. PubMed ID: 33753562
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
